Copyright
©2014 Baishideng Publishing Group Inc.
World J Cardiol. Jun 26, 2014; 6(6): 415-423
Published online Jun 26, 2014. doi: 10.4330/wjc.v6.i6.415
Published online Jun 26, 2014. doi: 10.4330/wjc.v6.i6.415
Registry type | Benefits | Negatives |
Academic | Limited external pressures for study; more flexibility in developing the dataset; lends itself to research; collaboration with many academic institutions and with Professional Bodies | Access to data provided by external sites may be limited; potentially limited funding; danger of “mission creep”-increasing data required; participating clinicians may become divorced from the academic group; difficult to enforce participation |
Insurance | Ready access to data through billing information; large amounts of data held; potential for internal data linkage; large populations to study; excellent case ascertainment | Inability to expand dataset outside that determined by insurance company/HMO; difficult to influence/alter datafield definitions; full access to data may not be available due to commercial sensitivity |
Industry sponsored | Well-funded; support for training of data collectors and encouragement of data entry; often based on access to new treatments | Limited sites; confidentiality clauses may restrict dissemination of findings; not all data widely available; may have strict patient selection (restricted to those receiving particular intervention); often time limited; less direct clinician control |
Government | National “reach”; can promote and mandate high levels of participation and data collection; collaboration between multiple agencies; large population for study | Limited sense of clinical ownership |
- Citation: Ashrafi R, Hussain H, Brisk R, Boardman L, Weston C. Clinical disease registries in acute myocardial infarction. World J Cardiol 2014; 6(6): 415-423
- URL: https://www.wjgnet.com/1949-8462/full/v6/i6/415.htm
- DOI: https://dx.doi.org/10.4330/wjc.v6.i6.415